Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

Authors:

Abstract
No abstract available
Funding Information
  • Bill & Melinda Gates Foundation
  • ViiV Healthcare
  • Janssen
  • Merck
  • Gilead Sciences
  • ViiV Healthcare
  • Gilead Sciences
  • Janssen
  • ViiV Healthcare
  • Merck
  • Bristol-Myers Squibb
  • AbbVie
  • Bill & Melinda Gates Foundation (OPP1045325)

This publication has 18 references indexed in Scilit: